Investor directory

Transgene

Transgene is a biotechnology company focused on the clinical research and development of immunotherapeutic products and therapeutic vaccines aimed at treating cancers and chronic infectious diseases. The company manages all aspects of product development, from research and clinical batch manufacturing to the execution of clinical trials. Transgene's clinical-stage programs include TG4010 for non-small cell lung cancer and Pexa-vec for liver cancer, alongside a diverse pipeline featuring additional candidates such as TG4001, TG1050, and TG6002. The majority of its operations are based in France.
http://www.transgene.fr
https://crunchbase.com/organization/transgene
https://linkedin.com/company/transgene
https://twitter.com/transgenesa
https://www.capitaliq.com/CIQDotNet/company.aspx?companyId=386045

Lucie Larguier

Vice President and CFO

1 past transactions

ElsaLys Biotech

Series A in 2013
ElsaLys Biotech SAS, a biotechnology company, designs and develops therapeutic antibodies that target tumors and their immune and/or vascular microenvironment. It offers research and development programs, ELB011 and ELB012 ophthalmology programs; and ELB021, ELB031, and ELB041 oncology programs. The company was incorporated in 2013 and is based in Lyon, France and additional location in Strasbourg, France. As of May 7, 2020, ElsaLys Biotech SA operates as a subsidiary of Mediolanum farmaceutici S.p.A.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.